Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3844022 | 0.86 | HTR6 (0.54) | HTR6HTR2BMEN1ALDH1A1KMT2A | |
| SCHEMBL3840327 | 0.83 | HTR6 (0.59) | HTR6ALDH1A1LMNA | |
| SCHEMBL3841936 | 0.83 | HTR6 (0.50) | HTR6HTR2BALDH1A1LMNAHTR2C | |
| SCHEMBL3840250 | 0.75 | HTR6 (0.67) | HTR6HTR2BALDH1A1LMNACHRM2 | |
| SCHEMBL315805 | 0.71 | HTR6 (0.80) | HTR6 | |
| SCHEMBL3840359 | 0.70 | HTR6 (0.57) | HTR6ALDH1A1LMNAHTTMAPK1 | |
| SCHEMBL3840272 | 0.70 | HTR2C (0.55) | HTR6HTR2BHTR2C | |
| SCHEMBL27752358 | 0.69 | HTR6 (0.58) | HTR6 | |
| SCHEMBL3839924 | 0.69 | HTR6 (0.64) | HTR6HTR2BALDH1A1LMNAHTR2C | |
| SCHEMBL30364101 | 0.69 | CHRNA7 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | claimed |
| CN-101124210-A | Tetrahydronaphthalene and indane derivatives and their use | ROCHE PALO ALTO LLC (CH) | 2008-02-13 | — | — | CN | claimed |
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-20 | — | — | US | claimed |
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| EP-1831189-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473690-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160825-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | HTR6 1638/4885HTR2B 2354/4885MEN1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.